GT Biopharma Reports Third Quarter 2026 Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GT Biopharma (NASDAQ: GTBP) reported a third-quarter 2026 net loss of approximately $3.5 million while advancing its early-stage cancer trials. The prior-year quarter had net income of $8.3 million, including $11.4 million in non-cash income from a liability valuation change absent this quarter. Research and development expenses rose to approximately $1.7 million from $0.6 million; selling, general and administrative expenses excluding stock compensation fell to approximately $1.8 million from $2.4 million.
Cash was approximately $10 million at September 30, 2026; the company expects funding into Q3 2027 and updates on both ongoing Phase 1 trials in Q4 2026. GTB-3650 enrollment reached Cohort 5, while GTB-5550 solid-tumor enrollment reached Cohort 3. The FDA cleared an investigational new drug application for GTB-5550 in multiple myeloma, but trial initiation depends on the timing and receipt of non-dilutive grant funding.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Cash of approximately $10 million at September 30, 2026 is expected to fund operations into Q3 2027.
- Moderate pointSG&A expenses excluding stock compensation fell to approximately $1.8 million in Q3 2026 from $2.4 million in Q3 2025.
- Minor pointGTB-5550 received FDA clearance for an investigational new drug application in multiple myeloma in September 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.GTB-3650 completed Cohort 4; Cohort 5 enrollment is ongoing, with an update expected in Q4 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.GTB-5550 solid-tumor trial completed Cohorts 1 and 2; Cohort 3 enrollment continues, with an update expected in Q4 2026.
3 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.GTB-5550 solid-tumor expansion plans to evaluate up to 7 tumor types after dose escalation.
- Minor point. Forward-looking: it has not happened yet and may not happen.GTB-5550 multiple-myeloma trial plans up to 6 dose cohorts, followed by a 25-patient expansion.
- Minor pointGTB-5550 combined with a KRAS inhibitor showed enhanced effects against pancreatic tumor cells in preclinical data.
Negative
- Major pointNet results shifted to an approximately $3.5 million loss in Q3 2026 from $8.3 million income in Q3 2025.
- Moderate pointR&D expenses increased to approximately $1.7 million in Q3 2026 from $0.6 million in Q3 2025, primarily on materials.
- Moderate point. Forward-looking: it has not happened yet and may not happen.GTB-5550 multiple-myeloma trial initiation is contingent on timing and receipt of non-dilutive grant funding.
- Minor pointPrior-year $11.4 million non-cash liability valuation income did not recur, primarily explaining the net-results deterioration.
- Minor pointOperating loss widened to approximately $3.5 million in Q3 2026 from $3.4 million in Q3 2025.
News Explained
At the
Key Figures
- Cash and cash equivalents
- approximately $10 million
- As of September 30, 2026
- Cash runway
- into the third quarter of 2027
- Anticipated runway based on cash as of September 30, 2026
- R&D expenses
- approximately $1.7 million vs. $0.6 million
- Third quarter 2026 vs. the same quarter of 2025
- SG&A expenses excluding stock compensation
- approximately $1.8 million vs. $2.4 million
- Third quarter 2026 vs. the same quarter of 2025
- Loss from operations
- approximately $3.5 million vs. $3.4 million
- Third quarter 2026 vs. the same quarter of 2025
- Net loss
- approximately $3.5 million vs. net income of $8.3 million
- Third quarter 2026 vs. the same quarter of 2025
Previous Earnings Reports
-
Reported approximately $5.1 million cash and runway through Q4 2026, with $4.5 million net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pharmacokinetics medical
pharmacodynamics medical
mtd medical
pfs medical
os medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with an update anticipated in Q4 2026
Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 remains ongoing, with an update anticipated in Q4 2026
FDA clearance of a new IND for GTB-5550 in multiple myeloma under an investigator sponsored trial protocol; Phase 1 trial initiation contingent upon timing and receipt of non-dilutive grant funding
Oral presentation at the SITC 2026 Annual Meeting on November 6, 2026 showcased new preclinical data demonstrating an enhanced effect of combining GTB-5550 with a KRAS inhibitor (KRASi), which was shown to sensitize pancreatic tumor cells to NK cell cytotoxicity
Cash balance as of September 30, 2026 of approximately
SAN FRANCISCO, CALIFORNIA, Nov. 16, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced third quarter 2026 financial results for the period ended September 30, 2026.
"This quarter we broadened the potential reach of GTB-5550 with FDA clearance of a new IND in multiple myeloma, while continuing to enroll patients in both of our ongoing Phase 1 trials," said Michael Breen, Executive Chairman and Chief Executive Officer. "This expansion reflects the versatility of our TriKE® platform, and our growing use of AI-based tools is helping us identify additional development candidates for 2027. With cash runway into Q3 2027, we are well positioned and look forward to providing updates on both Phase 1 programs in the fourth quarter."
GTB-3650 TriKE for CD33 positive leukemias
The ongoing Phase 1 dose escalation study is evaluating GTB-3650 for relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Enrollment is ongoing, with Cohort 4 complete and enrollment of Cohort 5 in progress. The Company expects to provide an update in Q4 2026.
Dose escalation may continue up to Cohort 7 as necessary with the potential to evaluate GTB-3650 in a total of 14 patients (two patients per cohort). GTB-3650 is dosed in two-week blocks, two weeks on and two weeks off, for up to four months based on clinical benefit. The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells and clinical activity.
GTB-5550 TriKE for B7H3 positive solid tumor cancers
The ongoing Phase 1 trial with GTB-5550 is the first nanobody TriKE® tested with more patient-friendly subcutaneous dosing. The Phase 1a dose escalation portion of the trial is focused primarily on enrolling prostate cancer patients and will evaluate up to 6 dose levels to identify the maximum tolerated dose (MTD). Enrollment in Cohort 1 and Cohort 2 is complete and enrollment in Cohort 3 is in progress. The Company expects to provide an update in Q4 2026.
After the dose escalation phase, the Phase 1b expansion component will enroll patients with up to 7 different tumor types (castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer) and further evaluate its safety, tolerability and preliminary anti-tumor activity.
GTB-5550 will be administered by subcutaneous (SQ) injection in the abdominal area for 5 consecutive days during Week 1 and Week 2 followed by 2 weeks of no treatment. One treatment cycle is 4 weeks in duration. Subsequent cycles receive treatment three times weekly for 2 weeks followed by 2 weeks of no treatment. A minimum of 2 cycles is planned, and patient-appropriate disease reassessment is performed after 2 cycles and every 8-12 weeks thereafter. Treatment may continue until disease progression, unacceptable toxicity, patient refusal, or treatment is no longer in the best interest of the patient. Patients are followed for 12 months to determine progression free survival (PFS) and overall survival (OS). More details can be found on clinicaltrials.gov with the identifier: NCT07541573.
GTB-5550 TriKE for multiple myeloma
In September 2026, the Company announced FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial protocol. Initiation of the Phase 1 trial in MM patients is contingent upon timing and receipt of non-dilutive grant funding. The Phase 1a/1b trial would be the first-in-human trial of a B7-H3-targeted TriKE® in MM and will use subcutaneous administration intended to extend the half-life relative to prior intravenous TriKE® formulations. The Phase 1a dose escalation portion will enroll 4th line and later patients with MM and evaluate up to 6 dose cohorts to identify the MTD. Following dose escalation, the Phase 1b expansion cohort will enroll a total of 25 patients treated at the MTD and further evaluate safety, tolerability and preliminary anti-tumor activity.
GTB-5550 will be administered by subcutaneous (SQ) injection in the abdominal area on 3 non-consecutive days per week during Week 1 and Week 2, followed by 2 weeks of no treatment. One treatment cycle is 4 weeks in duration, and this dosing schedule is repeated for each subsequent cycle. A minimum of 2 cycles is planned, and disease reassessment (monoclonal protein and free light chain analysis) is performed on Day 28 of each cycle. Patients with stable disease may continue for up to 4 cycles total, and those with a partial response or better may continue for up to 1 year. Patients are followed for 12 months from the first dose of GTB-5550 to determine progression-free survival (PFS) and overall survival (OS).
Third Quarter Ended September 30, 2026 Financial Summary
Cash Position: The Company had cash and cash equivalents of approximately
Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2026 were approximately
Selling, General and Administrative (SG&A) Expenses (Excluding Stock Compensation): SG&A expenses for the third quarter of 2026 were approximately
Loss from Operations: The Company reported a loss from operations for the third quarter of 2026 of approximately
Net Loss: The Company reported a net loss of approximately
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward- looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "aims," "will," "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that the use of these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include (i) the Company’s ability to continue as a going concern; (ii) the risk that if the Company experiences delays or difficulties in the enrollment of patients in clinical trials, those clinical trials could take longer than expected to complete and the Company’s receipt of necessary regulatory approvals could be delayed or prevented; (iii) the risk that the Company will need additional capital to conduct its operations and develop its products, and the Company’s ability to obtain the necessary funding is uncertain; (iv) the risk that the Company’s common stock may be delisted in the future if the Company is unable to maintain compliance with continued listing requirements; (v) the risk that the Company’s products may fail to achieve necessary safety and efficacy endpoints during clinical trials, which may limit the company’s ability to general revenues from therapeutic products and (vi) those other factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
LinkedIn |Facebook |X |Instagram | YouTube
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How long does GT Biopharma expect its September 2026 cash balance to last?
GT Biopharma expects its approximately $10 million in cash and cash equivalents at September 30, 2026 to fund operations into the third quarter of 2027.
When does GT Biopharma expect updates on its ongoing Phase 1 cancer trials?
GT Biopharma expects updates on both GTB-3650 and GTB-5550 in Q4 2026. GTB-3650 has completed Cohort 4 and is enrolling Cohort 5. The GTB-5550 solid-tumor trial has completed Cohorts 1 and 2 and is enrolling Cohort 3.
How many patients could GT Biopharma enroll in the GTB-3650 dose-escalation trial?
The GTB-3650 trial could evaluate 14 patients, with two patients per cohort, if dose escalation continues through Cohort 7 as necessary. The study evaluates patients with relapsed or refractory CD33-expressing blood cancers, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.